Physician profile
John W Flaherty
NPI 1821089301
$2,770.36
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $463 · 2021: $926 · 2022: $538 · 2023: $77.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $77.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $77.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $609.23 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $357.73 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $341.58 | 2019-2021 | |
| Lilly USA, LLC | $259.55 | 2019-2021 | |
| Pfizer INC. | $210.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.93 | 2019-2022 | |
| Abbott Laboratories | $148.36 | 2022-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $107.92 | 2019-2021 | |
| Abbvie INC. | $85.97 | 2021 | |
| Allergan, INC. | $68.45 | 2022 | |
| Gilead Sciences, INC. | $60.95 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $41.00 | 2020-2021 | |
| Eisai INC. | $33.77 | 2021 | |
| Astellas Pharma US INC | $33.74 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.09 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $27.50 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $26.48 | 2020 | |
| Hologic Sales and Service, LLC | $22.43 | 2023 | Aptima, Thinprep 2000 Processor |
| Teva Pharmaceuticals USA, INC. | $22.22 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.46 | 2020 | |
| Glaxosmithkline, LLC. | $14.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.27 | 2019 | |
| Amgen INC. | $13.89 | 2021 | |
| Sanofi Pasteur INC. | $13.82 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.70 | 2021 | |
| Daiichi Sankyo INC. | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.